GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

These are some of the trends in weight management retailers and manufacturers are keeping an eye on in the new year to help ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

These ‘GLP-1 agonists ... These drugs have unlocked the potential for a global market that is projected to surpass US$100 ...

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.